Sign in Subscribe
Pharmaceutical industry

BioTransplant Inc. Announces Phase I/II Trial for AlloMune Cancer System

Strategic Insights

— 1 min read

Enrollment and treatment have begun in a multi-center Phase I/II trial of the AlloMune Cancer System for therapy-refractory Hodgkin's and non-Hodgkin's lymphoma. The trial is designed to re-educate the body's immune system to accept foreign cells, producing powerful anti-tumor effects while minimizing severe graft-versus-host disease (GvHD). The AlloMune Cancer System builds upon a prototype system used at The Massachusetts General Hospital (MGH) to treat end-stage lymphoma and leukemia patients, demonstrating an overall response rate of 67% in 21 patients.

Key Takeaways:

  • The AlloMune Cancer System uses a combination of low-dose chemotherapy and antibodies against T cells to prepare patients for a bone marrow or stem cell transplant.
  • The system aims to reduce chemotherapy-related toxicity, potentially increase anti-tumor effects, and decrease the incidence and severity of GvHD.
  • BioTransplant has developed the AlloMune family of products to treat various medical conditions, including cancer, organ and tissue transplantation, hematological disorders, and autoimmune diseases.
  • The company has issued two U.S. patents (numbers 6006752 and 5876708) covering the induction of human tolerance to grafts from human and non-human donors through the creation of mixed chimerism.
  • MGH physicians have previously reported the successful treatment of a patient with both kidney failure and multiple myeloma using an AlloMune prototype system.
  • The treatment involved a double transplant of both bone marrow and a kidney from the patient's sister, with the immunosuppression discontinued on the 73rd day after the procedure.

Statistics:

  • The overall response rate for the AlloMune prototype system in 21 patients was 67% (38% complete response, 29% partial response).
  • The system has demonstrated potential to reduce chemotherapy-related toxicity and increase anti-tumor effects.
  • GvHD incidence and severity are reduced using the AlloMune system.
  • The AlloMune Cancer System aims to minimize the need for lifelong anti-rejection drugs and induce long-term functional tolerance.

Sources:

  • "BioTransplant Inc. - Multi-Center Phase I/II Trial for AlloMune Cancer System", NewsRx.com, APR 18, 2000.
  • Annual Meeting of the American Society of Hematology (ASH).
  • "The Lancet", published in 1999.
  • "Transplantation" journal, previously reported a patient's successful treatment using an AlloMune prototype system.

Read more